Calamos Wealth Management LLC Cuts Stake in Boston Scientific Corporation $BSX

Calamos Wealth Management LLC lowered its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 117,214 shares of the medical equipment provider's stock after selling 37,824 shares during the quarter. Calamos Wealth Management LLC's holdings in Boston Scientific were worth $11,176,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of BSX. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp increased its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. United Community Bank increased its holdings in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares in the last quarter. Finally, Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Boston Scientific from $94.00 to $75.00 and set an "overweight" rating for the company in a report on Thursday. National Bank Financial set a $115.00 price target on shares of Boston Scientific in a report on Monday, February 2nd. Morgan Stanley cut their price target on shares of Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Jefferies Financial Group dropped their target price on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Stifel Nicolaus dropped their target price on shares of Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.91.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation NYSE: BSX Q1 2026 Earnings Call Transcript
• Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options NYSE: BSX
• Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
• Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific NYSE: BSX Hits New 52-Week Low After Analyst Downgrade

Boston Scientific Stock Performance

NYSE:BSX opened at $62.01 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $68.45 and a two-hundred day moving average price of $85.78. Boston Scientific Corporation has a twelve month low of $59.38 and a twelve month high of $109.50. The company has a market capitalization of $92.16 billion, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 1.08 and a beta of 0.78.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm posted $0.75 EPS. The firm's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.